H2K2 Stock Overview
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
XTL Biopharmaceuticals Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₪2.24 |
| 52 Week High | ₪3.06 |
| 52 Week Low | ₪0.64 |
| Beta | 1.03 |
| 1 Month Change | -21.13% |
| 3 Month Change | 217.73% |
| 1 Year Change | 109.35% |
| 3 Year Change | -15.15% |
| 5 Year Change | 14.87% |
| Change since IPO | -98.50% |
Recent News & Updates
Recent updates
Shareholder Returns
| H2K2 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -5.9% | -0.7% | 2.5% |
| 1Y | 109.3% | -21.2% | 5.4% |
Return vs Industry: H2K2 exceeded the German Biotechs industry which returned -23.6% over the past year.
Return vs Market: H2K2 exceeded the German Market which returned 4.6% over the past year.
Price Volatility
| H2K2 volatility | |
|---|---|
| H2K2 Average Weekly Movement | 42.6% |
| Biotechs Industry Average Movement | 5.3% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 10.5% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: H2K2's share price has been volatile over the past 3 months.
Volatility Over Time: H2K2's weekly volatility has increased from 25% to 43% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1993 | n/a | Shlomo Shalev | www.xtlbio.com |
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases. Its lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren’s syndrome. It has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications.
XTL Biopharmaceuticals Ltd. Fundamentals Summary
| H2K2 fundamental statistics | |
|---|---|
| Market cap | €12.21m |
| Earnings (TTM) | -€1.65m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-7.4x
P/E RatioIs H2K2 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| H2K2 income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$1.78m |
| Earnings | -US$1.78m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0033 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did H2K2 perform over the long term?
See historical performance and comparison